Skip to main content
Premium Trial:

Request an Annual Quote

2023 Virtual Molecular Tumor Board Series

2022 virtual molecular tumor board series

 

About the Series

The 2023 Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Speakers

Howard McLeod webinar speaker profile image

Howard McLeod, PharmD

Medical Director, Precision Medicine
Geriatric Oncology Consortium

Read more

Dr. Howard McLeod is the Medical Director for Precision Medicine at the Geriatric Oncology Consortium. He is an internationally recognized expert in pharmacogenomics and personalized medicine, having made contributions at the discovery, translation, implementation, and policy levels. He is a Professor at the University of South Florida Taneja College of Pharmacy. He was previously the Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center. He also chaired the Department of Individualized Cancer Management, was a Senior Member in the Department of Cancer Epidemiology, and a State of Florida Endowed Chair in Cancer Research. Dr. McLeod chaired the NHGRI eMERGE network external scientific panel for the past decade and was a recent member of both the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council.

Since 2002, Dr. McLeod has been vice chair for Pharmacogenomics for the major NCI clinical trials group, overseeing the largest oncology pharmacogenomics portfolio in the world. Dr. McLeod is a Fellow of the American Society of Clinical Oncology and the American College of Clinical Pharmacy. Howard has published over 560 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance individualized medicine.

Porscha Johnson Williams

Porscha Johnson Williams, Pharm.D.

Clinical Pharmacist
Northside Hospital of Atlanta

Read more

Dr. Porscha Johnson Williams is a graduate of the University of North Carolina at Chapel Hill, and received her Doctor of Pharmacy degree from Howard University College of Pharmacy in Washington, DC. Shefurthered her training through thecompletion ofa post-doctoral clinical pharmacy fellowship in Hematology/Oncology and Critical Care at Howard University Hospital. Currently, Porscha practices as a clinical pharmacist at Northside Hospital of Atlanta where she specializes in caring for medical oncology and bone marrow transplant patient populations. She collaborates with a multidisciplinaryteam for treatment decisions, and develops and maintains chemotherapy and supportive care protocols, policies and procedures according to cutting edge research within the field. Furthermore, Porscha oversees and contributes to many hospital-wide and department initiatives, the development and delivery of educational material and presentations to all disciplines, as well as serves as an independent consultant for pharmacogenomics to ensure the exceptional care for all patients.

Christine Walko webinar speaker profile image

Christine Walko, PharmD, BCOP, FCCP

Associate Member in the Department of Individualized Cancer Medicine and Program
Lead for the Precision Medicine Program at Moffitt Cancer Center

Read more

Christine M. Walko is a Personalized Medicine Specialist at the DeBartolo Family Personalized Medicine Institute at the H. Lee Moffitt Cancer Center and is also Associate Professor at the University of South Florida Morsani College of Medicine in Tampa, Florida. She is also the Chair of the Clinical Genomics Action Committee (CGAC) and an Attending on the Personalized Medicine Clinical Service at H. Lee Moffitt Cancer Center. Dr. Walko received her Doctor of Pharmacy from Duquesne University in Pittsburgh. She completed a pharmacy practice residency at Virginia Commonwealth University Health System/Medical College of Virginia Hospitals in Richmond, Virginia. She also completed a Hematology/Oncology specialty residency at the University of North Carolina (UNC) Hospitals and Clinics and a Hematology/Oncology fellowship at the University of North Carolina School of Pharmacy in Chapel Hill, North Carolina. She is a board-certified oncology pharmacist.

Aneesa Al-Soodani, PhD

Aneesa Al-Soodani, PhD

Variant Scientist
Intermountain Precision Genomics

Read more

Aneesa obtained her BS in biology from the University of Portland and her PhD in molecular biosciences from Washington State University. Her dissertation focused on the regulation of DNA double-strand break repair in the laboratory of Dr. Chengtao. Aneesa then went on to serve as a post-doctoral scholar at the University of Utah chemistry department where she investigated the transcriptional regulation of a family of methyl-binding proteins in prostate cancer. She is now a variant scientist at Intermountain Precision Genomics where she classifies and curates genomic variants. She is passionate about utilizing complex datasets for clinical applications.

Mary Walters, PharmD, BCOP

Mary Walters, PharmD, BCOP

Clinical Pharmacist
Advocate Aurora Health

Read more

Mary Walters is a clinical pharmacist at Advocate Health based out of Milwaukee. She has served as the organization’s co-director of the oncology precision medicine program since 2021 and an oncology pharmacy specialist since 2018. She received her Doctor of Pharmacy degree with a research emphasis from the University of Minnesota, Twin Cities in 2016, graduating with high distinction. Following graduation, Walters completed a PGY-1 pharmacy practice residency with North Memorial Health in Robbinsdale, Minnesota and PGY-2 oncology pharmacy specialty residency at Advocate Health. Walters is board certified as an oncology pharmacist by the American College of Clinical Pharmacy and is an active member of the Hematology Oncology Pharmacy Association and the Pharmacy Society of Wisconsin, serving as BCOP reviewer and author, as well as a Pharmacogenomics and Genetics Committee member. Walters also leads the Advocate Health Oncology Molecular Tumor Board and Genomic Testing Committee.

Ben Kong, PharmD, BCPS

Ben Kong, PharmD, BCPS

Clinical Pharmacist
Oregon Health and Science University

Read more

Dr. Ben Kong is a board-certified clinical pharmacist specialist and currently practices at Oregon Health & Science University (OHSU). He received his honors BS and PharmD from Oregon State University. He completed a PGY-1 residency at Providence Health & Services in Portland, Oregon and a PGY-2 residency at University of Florida specializing in clinical pharmacogenetics and implementation initiatives. To this day, he continues to be involved in various national organizations to advance the field of personalized medicine.

In his current role, he is a member of the OHSU Knight Cancer Institute’s Precision Oncology SMMART program (Serial Measurements of Molecular and Architectural Responses to Therapy) and collaborates with clinicians and scientists to understand tumor biology in order to develop treatment tailored to the individual patient.

Sessions

Impact of Emerging and Evolving Biomarkers and Associated Treatment Options on Cancer Therapy Prioritization

This webinar is part one of the four-part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which recently FDA-approved treatment options based on emerging and evolving biomarkers present new options for cancer therapy prioritization in various solid tumor settings. 

Most notably, clinically actionable biomarkers such as KRAS G12C, ESR1, HLA-A *02:01, FR-alpha, and the revolutionary HER2-low subtype designation, have introduced treatment options that previously did not exist for such niche oncology populations.

Our panel will address these biomarkers within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Register Now

What’s Best for Breast: Treatment Implications for the Expansion of Biomarker Utility in Breast Cancer

This webinar is part two of the four-part virtual molecular tumor board series.

In this tumor-specific session, our expert panelists will review patient cases in which genomic profiling has identified an array of clinically actionable alterations that make patients eligible for targeted therapies for breast cancer.

Most notably, the recent advancement of biomarkers such as ESR1 and the evolution of the HER2-low expression subtype have introduced FDA-approved treatment options that previously did not exist for such niche oncology populations. The availability of multiple layers of biomarker information has the potential to better inform individualized treatment plans and enhance patient outcomes.

Our panel will address various treatment opportunities within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Register Now

Lung Cancer: An Update on the Clinical Impact of Genomic Profiling for Treatment Selection Decision-Making

This webinar is part three of the four-part virtual molecular tumor board series.

In this tumor-specific session, our expert panelists will discuss in detail several clinical cases where extensive genomic profiling was conducted and used to recommend a course of treatment for lung cancer patients based on the prioritizing of available data.

Clinical decisions for deliberation include validating biomarkers for targeted therapy and immunotherapy, how to address co-occurring genomic alterations, and considerations for duration and de-escalation of immunotherapy according to provider preference and supporting literature.

Our panel will address various treatment opportunities within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Register Now

GI/GU Cancers: Therapy Considerations from a Genomics Perspective

This webinar is part four of our four-part virtual molecular tumor board series.

In this tumor-specific session, our expert panelists will review patient cases in which the clinical utility of genomics has presented various therapy considerations for patients diagnosed with gastrointestinal and genitourinary cancers.

Discussions will address homologous recombination deficiency (HRD), the evaluation of fusion-positive malignancies, as well as resistance mechanisms following targeted therapy and thoughts on re-challenging a patient.

Our panel will address these challenges and opportunities within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

Register Now